Enhanced Antitumor Activity of EGFP-EGF1-Conjugated Nanoparticles by a Multitargeting Strategy

ACS Applied Materials & Interfaces
Bo ZhangZhiqing Pang

Abstract

Tumor stromal cells have been increasingly recognized to interact with tumor parenchyma cells and promote tumor growth. Therefore, we speculated that therapeutics delivery to both parenchyma cells and stromal cells simultaneously might treat a tumor more effectively. Tissue factor (TF) was shown to be extensively located in a tumor and was abundantly sited in both tumor parenchyma cells and stromal cells including neo-vascular cells, tumor-associated fibroblasts, and tumor-associated macrophages, indicating it might function as a favorable target for drug delivery to multiple cell types simultaneously. EGFP-EGF1 is a fusion protein derived from factor VII, the natural ligand of TF. It retains the specific TF binding capability but does not cause coagulation. In the present study, a nanoparticle modified with EGFP-EGF1 (ENP) was constructed as a multitargeting drug delivery system. The protein binding experiment showed EGFP-EGF1 could bind well to A549 tumor cells and other stromal cells including neo-vascular cells, tumor-associated fibroblasts, and tumor-associated macrophages. Compared with unmodified nanoparticles (NP), ENP uptake by A549 cells and those stromal cells was significantly enhanced but inhibited by excessive fre...Continue Reading

References

Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·Z Hu, A Garen
Apr 17, 2002·International Journal of Pharmaceutics·Franz GaborMichael Wirth
Jul 24, 2002·Clinical Biochemistry·Ming GuanYuan Lu
Sep 8, 2004·Advanced Drug Delivery Reviews·Lisa Brannon-Peppas, James O Blanchette
Jul 14, 2006·Molecular Biology of the Cell·Shu JiangBrian Storrie
Jul 25, 2006·The Journal of Clinical Investigation·Yunping LuoRong Xiang
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Fernando O MartinezAlberto Mantovani
Apr 1, 2008·Breast Cancer Research : BCR·Joanne E BluffCarolyn A Staton
Apr 26, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Zhiqing PangCuiqing Zhu
May 7, 2009·International Journal of Pharmaceutics·Jiang ChangDidier Betbeder
Jul 25, 2009·Journal of Thrombosis and Haemostasis : JTH·T C Carneiro-LoboR Q Monteiro
Feb 16, 2010·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Heng MeiTao Guo
Apr 7, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jai PrakashKlaas Poelstra
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jun 10, 2011·International Journal of Pharmaceutics·Zhiqing PangXinguo Jiang
Nov 24, 2011·International Journal of Molecular Medicine·Qing ZhangXu Song
Jun 15, 2012·Thrombosis Research·Begüm Kocatürk, Henri H Versteeg
Aug 23, 2012·Journal of the National Cancer Institute·W Nathaniel BrennenSamuel R Denmeade
Jan 5, 2013·The Oncologist·Marion Cole, Michael Bromberg
Sep 21, 2013·Proceedings of the National Academy of Sciences of the United States of America·Maryelise CieslewiczSuzie H Pun
Sep 24, 2013·Nature Medicine·Stephanie M PyonteckJohanna A Joyce
Oct 15, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Huile GaoXinguo Jiang
Oct 24, 2013·Nature Materials·Vikash P Chauhan, Rakesh K Jain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.